NeurogesX is assembling a portfolio of non-opioid pain management product candidates and innovative new therapies. Qutenza® (NGX-4010) and NGX-1998 are both dermal applications of the same active ingredient, a highly pure synthetic capsaicin focused on treating peripheral neuropathic pain. The Company's preclinical pipeline consists of two prodrug programs derived from well known, widely used pain drugs that have a modified chemical make-up to potentially improve safety, efficacy and/or usefulness.
Our lead product, Qutenza, has the potential to redefine neuropathic pain treatment because, unlike current therapeutic options, a single 60-minute application can provide 3-months of pain relief.
NEUROGESX INVESTIGATIONAL PRODUCT PIPELINE
Qutenza is approved in the United States for the management of pain associated with PHN.
In clinical trials, the most common adverse reactions were application-site redness, pain, itching, and papules. The majority of these reactions were transient and self-limited. Serious adverse reactions included application site pain and increased blood pressure. Blood pressure increases during or shortly after Qutenza treatment were on average less than 10 mm Hg, although some patients had greater increases and these changes lasted for approximately 2 hours after patch removal. Increases in blood pressure were unrelated to the pre-treatment blood pressure but were related to treatment-related increases in pain.